Skip to content

A Longitudinal Study to Investigate and Develop a Patient-centered and Effective Fatigue Screening

Müdigkeit Und Erschöpfung Rechtzeitig Erkennen Und LINdern - a Longitudinal Study to Investigate and Develop a Patient-centered and Effective Fatigue Screening

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05448573
Acronym
MERLIN
Enrollment
300
Registered
2022-07-07
Start date
2022-10-20
Completion date
2025-09-30
Last updated
2025-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer-related Fatigue

Brief summary

MERLIN will include 300 cancer patients at the beginning of their systemic cancer therapy. Patients' fatigue-levels will be surveyed at short time intervals during their cancer therapy and at longer intervals during the subsequent post-treatment phase.

Detailed description

MERLIN aims to answer the question, how a fatigue screening tool should be designed for use in clinical practice to reliably and efficiently detect fatigue in cancer patients. Patients will be surveyed at short time intervals during their cancer therapy (every 1-2 weeks) and at longer intervals during the subsequent post-treatment phase (every 4-6 weeks). In addition, important psychological factors, which may exacerbate fatigue or contribute to its maintenance will be assessed at baseline, after 3, 6, 12 and 18 months (e.g. depressive symptoms, anxiety, sleep disturbances, coping). These data will be collected by online questionnaires. Additional data, e.g. medical history, cancer characteristics and treatment as well as concomitant medication and complementary therapies will be extracted from the clinical documentation systems. In total, the study will provide important information for the establishment of a patient-oriented fatigue screening. Thus, MERLIN will contribute to the early detection and alleviation of this frequent and distressing side effect of cancer treatment.

Interventions

DIAGNOSTIC_TESTFatigue Screening and assessment

(Newly) diagnosed cancer-patients from any cancer entity. No intervention.

Sponsors

National Center for Tumor Diseases, Heidelberg
CollaboratorOTHER
German Cancer Research Center
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No

Inclusion criteria

* having received a cancer diagnosis (any entity, any stage) * before or within the first month of systemic therapy or radiotherapy against this cancer * age ≥ 18 years * having the ability to consent to the study

Exclusion criteria

* previous systemic cancer therapies or radiotherapy within the last 6 months * diagnosis of chronic fatigue syndrome / myeloid encephalitis * unable to understand the study protocol and complete scheduled assessments during the study period (e.g., for language, cognitive, medical, or organizational reasons) * not able to complete the survey online via smartphone, PC, or tablet

Design outcomes

Primary

MeasureTime frameDescription
1st fatigue screeningBaseline - 18 monthsbased on the first Cella-criterion, 3 (dichotomous) items
2nd fatigue screeningBaseline - 18 monthsVisual Analogue Scale (VAS) for Energy, 1 item (Numeric Rating Scale 0-10), higher values meaning higher energy levels.
3rd fatigue screeningBaseline - 18 monthsshort Fatigue impact, 1 item (Numeric Rating Scale 0-10), higher values meaning higher fatigue impact on daily functioning.
Cancer-related fatigue (as reference criterion)Baseline - 18 monthsbased on Cella criteria, 11 (dichotomous) items

Secondary

MeasureTime frameDescription
Occupational Issues (Present)T4 (18 months)Current working status, 4 items
Depressive symptoms and anxietyBaseline - 18 monthsassessed by the Patient Health Questionnaire (PHQ-4), 4 items. The items are rated on a 4-point scale ranging from 0 (not at all) to 3 (most of the time). A sum score is calculated, with higher scores meaning a higher level of depressive symptoms and anxiety
Physical activityBaseline - 18 monthsassessed by a questionnaire regarding walking, cycling, and exercise behavior
Sleep disordersBaseline - 18 monthsassessed by the PSQI (Pittsburgh Sleep Quality Index).The PSQI consists of open and closed questions regarding characteristics of sleep and sleep quality. Some items are rated on a 4-point likert scale with higher scores meaning more sleep problems.
EORTC single itemBaseline - 18 monthssuffering from hot flashes, 4-point Likert scale. A higher value means more suffering.
DistressBaseline - 18 monthsassessed by the Distress Thermometer, 0-10 Numerous Rating scale. Higher values meaning more distress
Occupational Issues (Past)T4 (18 months)Pre-diagnosis working status, 2 items
Social SupportBaseline - 18 monthsassessed by the Illness-specific Social Support Scale (ISSS, German Version) among cancer patients. The 8 items are rated on a 5-point Likert scale ranging from 0 (never) to 4 (always). Sum scores for the items 1,3,6 and 8 (positive support) as well as for the items 2,4,5 and 7 (detrimental interaction) are calculated with higher scores meaning higher levels of positive support and detrimental interaction respectively.
Fatigue Coping3 months - 18 monthsassessed by an adapted Brief COPE questionnaire. The questionnaire consists of 14 items and the items are rated on a 4-point Likert scale with higher scores meaning higher use of the coping strategy described
Multidimensional fatigueBaseline - 18 monthsEORTC QLQ - FA12 (physical, emotional, and cognitive dimension). The items are rated on a 4-point Likert scale ranging from 1 (not at all) to 4 (very much) with higher scores meaning a higher level of fatigue.
Fatigue impactBaseline - 18 monthsBrief Fatigue Inventory (BFI). The BFI consists of an 11-point numerical rating scale ranging from 0 (no fatigue) to 10 (as bad as you can imagine) with higher scores signifying higher intensity and impairment
Quality of life, function and symptomsBaseline - 18 monthsassessed by the EORTC QLQ-C30. The items are rated on a 4-point Likert scale ranging from 1 (not at all) to 4 (very much). A higher score corresponds to a higher level of symptoms/problems

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 8, 2026